CONFIDENTIAL POSITION SPECIFICATION
|Position||Head of Global Research and Clinical Development|
|Company||The Carolina Longevity Institute (CLI)|
|Location||Flexible and HQ in Research Triangle Park, NC|
|Reporting Relationship||Chief Executive Officer|
The Carolina Longevity Institute’s (CLI) mission is to extend, in collaboration with the longevity scientific and medical community, the healthy lifespan of humans to 120 years by 2040. The organization was founded by Greg Lindberg, a visionary and highly successful entrepreneur who is committed to enabling humans to live healthier and longer lives. CLI is headquartered in Research Triangle Park, NC.
CLI is advancing global longevity research and medical treatment and developing breakthrough personalized medicine approaches to greatly improve wellness and human health and to extend life expectancy while improving quality of life. The organization’s vision is to holistically manage wellness, nutrition and health, and to diagnose and treat diseases to significantly change the treatment paradigm for patients by using personalized medicine and cutting edge technologies. Additionally, CLI is deploying Eli Global’s highly successful M&A investment strategies and processes to build a portfolio of companies in the longevity and healthspan related ecosystem to include longevity clinics, supplements and nutraceuticals, genetics and precision medicine related labs, health products, artificial intelligence, and telemedicine.
CLI’s strategy is to establish a global network of research, clinical development, and medical institutions to further the organization’s mission. CLI has exceptional founders, experienced advisors, and committed investors. Strategically, the institute will advance its own initiatives, products and services, and also collaborate with international governments, regulators, businesses, additional investors, and other strategic partners across the globe.
In short, CLI is pioneering a dramatically innovative approach to advancing research, clinical development, and medical treatment to improve patients’ health and extend people’s lives.
BOARD OF DIRECTORS
Owner and Founder
Greg Lindberg is a longtime bootstrap entrepreneur and CLI’s owner and founder. His entrepreneurial journey began in 1991 when he started a small healthcare newsletter business with $5,000 and grew it without any outside equity to $1 million a year in profit. Along with his team, Mr. Lindberg created Eli Global by reinvesting that cash flow in over 100 acquisitions that have produced a compound annual growth rate of over 35% on equity capital, generated $1.75 billion in revenue, and created $20 billion in pro forma assets, including pending acquisitions. Mr. Lindberg’s success can be attributed to his focus on long-term thinking with an emphasis on healthcare, and “first who, then what” decision-making.
Chief Executive Officer
A seasoned executive with more than 30 years of diverse experience in the life sciences, healthcare, technology and private equity industries, Michael Holder leads CLI’s broad strategic vision and overall operations including product development, corporate strategy, sales, business execution, M&A activities, and fundraising transactions. Michael also leads and is responsible for development and management of CLI’s acquisitions and other strategic transactions in the longevity healthspan ecosystem.
As former Chairman and CEO of Organ Transport Systems Inc., a medical technology company that is a leader in heart preservation and transport, Michael was responsible for developing the LifeCradle® Heart Perfusion System, a heart transportation device that nourishes and preserves the organ during transport prior to transplantation. His work in product development, research, regulatory compliance, intellectual property, business development, fundraising, and governance included completing a strategic acquisition, recruiting high-level board members, raising $12 million in equity capital in multiple investment rounds, and developing and maintaining prominent international partnerships.
Michael’s prior experience also includes service as vice president of sales, operations, and finance for Premier Inc., a publicly traded hospital group purchasing organization; chief financial officer of Clarkston Potomac Group Inc., a leading enterprise software integration and technology firm; and chief financial officer of Beacon Eye Institute, a publicly traded provider of laser vision correction services until its sale to a strategic buyer. Michael also served as an executive in the Sam Walton family private equity fund, Heartland Capital Partners LP. He has also served on boards of numerous companies, including Organ Transport Systems Inc., Beacon Eye Centers Inc., Cypher LLC, and Loyalty Management Group Inc.
Michael holds an MBA from the Wharton School at the University of Pennsylvania and a B.S. in business administration from the Kenan-Flagler Business School at the University of North Carolina at Chapel Hill. He previously obtained his certification as a Certified Public Accountant in the State of Texas and is a member of the National Association of Corporate Directors
Chief Executive Officer
Chief Operations and Scientific Officer
With more than 35 years’ experience and demonstrated success in the Biopharmaceutical Drug Development and Investment Sectors, Brian Huber leads the scientific and operational activities within CLI.
As Managing Director and VP at Quintiles/IQVIA, Brian’s ten-year service included responsibility for drug investment, risk-based investments and partnerships, managing key pharma accounts across the clinical and commercial business sectors, and delivering clinical oversight to drive efficiency, risk mitigation, clinical outcomes, and profitability.
Brian’s prior experience over the course of 2 decades with GlaxoSmithKline and the National Cancer Institute of the National Institutes of Health and Cato BioVentures ranges from managing drug discovery and clinical drug development portfolios to achieve maximal patient value and company ROI and developing and managing key partnerships for financial growth, clinical delivery and execution, and profitability, to identifying, structuring, and managing innovative clinical investments involving biopharmaceutical companies, core GP investors, and 3rd party syndicated capital sources.
Brian holds a Ph.D. in Pharmacology from The George Washington University and a BS and MS from Villanova University. He is also Board Certified in Clinical Pharmacology. He has completed residency programs in Advanced Leadership from the Kenan-Flagler Business School at the University of North Carolina at Chapel Hill and the London Business School. Brian has authored over 60 peer reviewed publications, is on 12 issued patents, and published a number of books. He holds adjunct academic positions at Duke University and The George Washington University.
Dr. Elaine Chin, who serves as an advisor to CLI, is a seasoned medical doctor, health coach, and bestselling author. Throughout her career, she has worked to help people live longer and have more rewarding, disease- and disability-free lives. She is a North American thought leader and recognized expert in personalized medicine, which leverages biometric and digital platform technologies – along with predictive analytics – to improve the health and performance of individuals.
Dr. Chin is the founder and medical director of Innovation Health Group, a provider of enterprise wellness programs delivered on a virtual platform, and Executive Health Centre, a premiere personalized medicine practice in Toronto, Canada. In January 2018, she joined the Good Housekeeping Magazine team as its health and wellness medical consultant. As a monthly column contributor, Elaine reaches more than 30 million readers monthly on health and wellness topics important to this brand’s print and online audiences.
Most recently, she served as chief wellness officer at TELUS Communications, with a focus on delivering world-class wellness programs to Canadians by integrating digital health technology and precision medicine. She currently serves as Heath Leader-In-Residence at the Odette School of Business at the University of Windsor, and she is part of an academic team that drives results at the World Health Innovation Network (WIN).
Dr. Chin has written Lifelines: Unlocking the Secret of Your Telomeres for a Longer, Healthier Life, which appeared on Canada’s Globe and Mail’s Top 10 Best Seller List. She received her medical degree from the University of Toronto, Canada, and her MBA from the same university’s Rotman School of Management.
Organizational Development Manager
As Organizational Development Manager, Michele Bowman assists CLI with startup and legal issues, and works with the recruiting and editorial teams and company leaders to create and review content, staff the company, and ensure smooth transitions for the business from stage to stage.
An attorney in the area of compliance and business law, Michele focuses on intellectual property, compliance plans, contract review, and other business matters in her position as director of compliance for ProEdTech, a professional training company. She is an experienced writer and editor in the areas of healthcare compliance, HR, law, finance and education, and formerly worked as a legal marketing professional for law firms in New York City including Proskauer Rose, Schulte Roth & Zabel, and others.
Ms. Bowman holds a JD from the University of Texas School of Law, an MFA from the University of North Carolina–Greensboro in creative writing, and a BA from the University of Texas at Austin in its honors liberal arts program.
As the Editorial Director for CLI, Erin Masercola curates all content for the website and associated publications. She has extensive experience in writing, launching, and leading healthcare publications, such as Health Information Compliance Alert, SuperCoder (https://www.supercoder.com) and Eye Care Leaders magazine. Dr. Masercola ’s interest in scientific and medical writing goes back to her time as a teaching fellow at UNC-CH, where she taught writing classes tailored for biology undergrads and med students. She also worked with molecular biologists to write then-new curricula for regional university students and to secure the funding necessary for all biology majors in North Carolina to have access to molecular biology lab experience as part of their education.
Dr. Masercola holds a Ph.D. in English from the University of North Carolina at Chapel Hill and a B.A. in English from the University of Texas at Austin.
Carolina Longevity Institute (CLI) is seeking a Head of Global Research and Clinical Development (HGRCD) who, as a strategic partner to the Chief Executive Officer and a member of the organization’s leadership team, will develop, lead and drive global research and clinical trial strategy and related initiatives to extend patients’ life expectancy while improving quality of life.
The HGRCD will be responsible for leading research and clinical trial site selection, startup, oversight and management activities a as well as regulatory affairs for longevity and health span therapies. The ideal candidate will actively participate in research and clinical trial strategic planning, partnering, execution, as well as the development of high-level communications and presentations to Eli Global’s owner Greg Lindberg. The HGRCD will also be expected to develop and maintain related constituent relationships and serve as an outward-facing representative of CLI with global key opinion leaders, government representatives, and the like, as well as to the medical scientific and public-investment communities.
The successful candidate will have demonstrated experience and capabilities in leading the evaluation, selection, startup and management of progressive research and clinical trials in sovereign and/or emerging countries. This person will have pre-existing as well as newly cultivated relationships with key international government, regulatory, medical community, and private industry individuals. This person will have a comprehensive understanding of and experience in this arena to successfully undertake and further CLI’s progressive research and clinical trial objectives. Also, CLI plans to invest in infrastructure of the sovereign and/or emerging countries (whether on a necessary or opportunistic basis) to facilitate its research and clinical trial objectives. The ideal candidate will have experiences identifying, facilitating, and managing such investments in addition to monitoring and furthering the related research and clinical trials.
The HGRCD will also leverage the successful candidate’s interest in and passion for longevity and health span medicine and her/his ability to develop related relationships with key opinion leaders and leading longevity research centers (nationally and internationally) to identify and cultivate global opportunities for CLI to invest in promising longevity and health span-related clinical trials, research, investments and acquisitions.
The HGRCD fulfills a critical and highly visible role, making substantial clinical and medical contributions to CLI and Eli Global’s owner, Greg Lindberg. Charged with the successful strategic positioning and tactical advancement of CLI’s preclinical and clinical programs, the HDRCD assumes ownership over CLI research and clinical trial strategies and activities and is responsible for ensuring professional and overall excellence in related development efforts. The HGRCD supports financing and strategic campaigns, playing a role of responsibility as needed in business and portfolio development and M&A activities. This person is a critical component of CLI’s executive management team.
The successful candidate will embrace and exemplify CLI’s values and corporate culture and be guided by CLI’s mission and goals on multiple fronts. The candidate will be articulate about and develop a fund of knowledge in the field of longevity and health span medicine and have a demonstrated ability to develop business and build excellent working global relationships internally and externally. This person must have the ability to successfully and confidently operate in an entrepreneurial environment and decentralized organization. The successful candidate will also have a strong intellectual curiosity, universally respected intelligence, and business savvy as well as the ability to think strategically and independently, to negotiate with and influence key stakeholders and decision makers and a “hands on” approach with attention to detail.
Areas of specific responsibility and attention will include the following:
- Identify optimum sovereign and emerging nation venues in which to establish a CLI presence in accordance with CLI’s mission and goals.
- Actively lead, manage, and conduct CLI’s research and clinical trials, and regulatory for longevity and healthspan therapies.
- Assume ownership over CLI research and clinical trials and related CLI programs and responsibility for ensuring professional and medical excellence in all development efforts.
- Represent CLI (in accordance with the organization’s mission, goals, and culture) in key interactions with U.S. and international regulatory, health, and sovereign agencies to support the advancement of key programs.
- Actively cultivate and maintain relationships with key government, regulatory, medical, and private industry officials in furtherance of identifying and selecting optimum site venues and to enhance the processes for leading, managing, and conducting CLI’s research and clinical trials, and regulatory for longevity and healthspan therapies.
- Nurture and sustain relationships with key government, regulatory, medical, and private industry officials for the purposes of identifying and developing promising longevity and healthspan-related investment and acquisition opportunities for CLI.
- Establish and maintain global collaborations with partners in academia, government, and industry.
- Identify potential CLI investment and M&A opportunities.
- Identify, facilitate, and manage investments in infrastructure within sovereign venues in which research and clinical trials are conducted in addition to managing and monitoring the related research and clinical trials.
- Work closely with the business, commercial, and regulatory functions to strategize drug development paths that seek to deliver timely regulatory approvals in areas of defined commercial merit.
- Actively assist in seeking product and/or technology alliances with appropriate and strategically-aligned pharmaceutical company partners to enhance/expedite the development of company assets.
- Actively participate in the development of strategic plans that support the R&D, mission and commercial goals of CLI.
- Effectively communicate the benefits of CLI’s product candidates through interactions with key opinion leaders, regulatory authorities, academic institutions, medical community, private industry, and advisors.
- Actively maintain an understanding of competitors and clinical developments in relevant therapeutic areas by attending scientific meetings and tracking literature.
- Confidently and productively lead and operate in an entrepreneurial environment and decentralized organization.
The successful candidate will have a passion for the mission of CLI and must have proven experience in successfully leading integrated global approaches to building, developing, and managing international research and clinical development activities and operations.
The ideal candidate must have experience in clinical development, medical and government affairs, and regulatory, ideally with previous contract research organizations or biopharmaceutical experience in emerging nations. This person will have deep, existing relationships with key international stakeholders and a thorough understanding of all the necessary requirements and processes.
The ideal candidate will also possess the following experience and qualifications:
- Strong business leadership skills and proven industry experience in leading international research and clinical development site selection, initiating and conducting clinical trials, and regulatory.
- Ability to support CLI business development and M&A activities and work effectively in corporate partnerships.
- Successful track record of interactions with international regulatory agencies (FDA, EMA and MHRA).
- Credibility within the international medical and scientific community. Ability to forge solid personal and professional relationships with key opinion leaders is desired.
- Strong external presence and proven track record of excellent interpersonal skills with experience presenting to and communicating with a wide variety of audiences including internal CLI teams, Eli Global’s owner and leadership team, strategic partners, government and medical/scientific communities.
- Solid organization skills and a good reputation for managing and influencing others to succeed.
- Hands-on style with proven ability to work in an entrepreneurial environment and ability to manage and outsource work as required.
- Solid business skills and judgment with an ability to evaluate alternatives, establish priorities and apply resources effectively.
- Demonstrated ability to lead and scale multi-disciplinary research and clinical teams across cultures.
- Strong judgment and decision-making skills in making critical go/no-go decisions.
- Self-motivated, assertive, and driven. An energetic entrepreneurial planner and builder rather than a “steady state manager.”
- Effective at identifying and engaging business, government, scientific, medical, and regulatory experts in order to capture value-creating options, and to refine and implement plans.
- Effective at synthesizing the scientific and medical literature to make informed decisions and determine best development pathways and investment opportunities.
- Ability to travel 40% domestically and internationally.
- Unquestionable integrity and highest ethical standards.
A bachelor’s degree is required. A graduate degree in a relevant scientific discipline is desired.
The compensation package will be designed to include a competitive base salary, bonus structure, and equity participation.
KORN FERRY CONTACTS
|Paul Pospisil, Ph.D.
Senior Client Partner,
Biotechnology & Pharmaceuticals
200 Park Avenue
New York, NY 10166
|Jasmine Ferrer, Ph.D.
Senior Client Partner,
Biotechnology & Pharmaceuticals
1650 Arch Street, #2300
Philadelphia, PA 19103
Senior Client Partner
2101 Cedar Springs Road
Senior Associate, Biotechnology & Pharmaceuticals
1650 Arch Street, #2300
Philadelphia, PA 19103